Pfizer Vaccine 97% Effective In Symptomatic COVID-19 Cases

The COVID-19 vaccine from Pfizer-BioNtech offers at least 97% effectiveness in symptomatic coronavirus cases.

The COVID-19 vaccine from Pfizer-BioNtech offers at least 97% effectiveness in symptomatic coronavirus cases, revealed real world data published by the pharma company.

The analysis, based on real world data gathered by the Israel //Ministry of Health, also found the vaccine's effectiveness at 94 per cent against asymptomatic SARS-CoV-2 infections.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

"We are extremely encouraged that the real-world effectiveness data coming from Israel are confirming the high efficacy demonstrated in our Phase 3 clinical trial and showing the significant impact of the vaccine in preventing severe disease and deaths due to Covid-19," Luis Jodar, Senior Vice President and Chief Medical Officer, Pfizer Vaccines, said in a statement.

This comprehensive real-world evidence can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization (WHO) declared Covid-19 a pandemic, the statement said.

In January, Pfizer and the Israel MoH entered into a collaboration agreement to monitor the real-world impact of the Pfizer-BioNTech Covid-19 vaccine.

World's First Hybrid Freezer for Covid-19 Vaccine Launched
Rockwell Industries, a pioneering commercial cold chain appliances manufacturer, on Thursday launched Chillermill, the world's first chiller/freezer powered by hybrid (solar and wind) renewable energy, that would be ideal for storing vaccines including Covid-19 vaccines at the desired temperature.

The findings from the analysis were derived from de-identified aggregate Israel MoH surveillance data collected between January 17 and March 6, 2021.

For all outcomes, vaccine effectiveness was measured from two weeks after the second dose.

India's First Covid-19 Vaccine 'Covaxin' Has No Serious Side Effects
Covaxin, India's first indigenous vaccine for Covid-19, is safe, immunogenic with no serious side effects . Bharat Biotech's phase 3 results show that Covaxin vaccine demonstrated 81% interim efficacy in preventing Covid-19, in those without prior infection, after the second dose.

Source-IANS

Pfizer COVID-19 Vaccine Effective From Day 11 Post 1st Dose
One dose of the Pfizer-BioNTech COVID-19 vaccine is sufficient in providing a robust immune response 11 days after inoculation against coronavirus.

TOP INSIGHT

Unvaccinated individuals were 44 times more likely to develop symptomatic Covid-19 and 29 times more likely to die from this virus-borne disease. Pfizer-BioNtech COVID-19 vaccine offers at least 97% effectiveness.